fda compounding semaglutide crackdown news today 2025 The is drawing a harder line on compounded weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA enforcement The GLP-1 drug shortage is

Yumuk V, Tsigos C, Fried M, et al

Based on available research and anecdotal reports: Week 1 to 2: Initial reduction in inflammation and pain may be noticed Some users report improved mobility at injury sites Gastrointestinal benefits may become apparent for those using oral forms Week 2 to 4: More noticeable improvements in tissue healing Continued reduction in inflammation Enhanced range of motion and functional recovery Week 4 to 8: Significant structural improvements in healing tissues Continued functional gains Many users report substantial recovery milestones The peptide has a relatively short half-life of less than 30 minutes, following linear pharmacokinetics after administration

These are two different measurements and both are true depending on where you start counting

(Cochrane Skin Group) (June 2019)